Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.

Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. Leuk Res. 2021 12; 111:106736.

View in: PubMed

subject areas

Antineoplastic Agents
Female
Follow-Up Studies
Humans
Leukemia, Myeloid, Acute
Maintenance Chemotherapy
Male
Middle Aged
Neoplasm Recurrence, Local
Prognosis
Prospective Studies
Quinolones
Salvage Therapy
Survival Rate

authors with profiles

Richard A. Larson
Lynne S. Kaminer